Eli Lilly | LLY - Current Assets


Eli Lilly reported $54.84B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Abbott USD 25.51B 488M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Baxter International USD 6.85B 25M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Drreddys Laboratories INR 301.98B 298.66B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Medtronic USD 24.07B 75M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novo Nordisk DKK 177.32B 4.86B Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Phibro Animal Health USD 894.07M 31.88M Mar/2026
Prestige Brands USD 431.48M 1.94M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.16B 789M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Zoetis USD 6.47B 294M Mar/2026